Jay Pepose, MD
Ophthalmology · Chesterfield, MONPI 1134111446
Payments from drug & device makers
Across 292 payments — averaging $1833.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oyster Point Pharma, Inc.$421K
- Bausch & Lomb Americas Inc.$22K
- Sun Pharmaceutical Industries Inc.$19K
- Kala Pharmaceuticals, Inc.$15K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$14K
- Alcon Research LLC$9K
- plus $36K from 24 others
What the payments were for
- Consulting fees$460,91889%
- Speaking & faculty fees$30,6766%
- Travel & lodging$15,9373%
- Food & beverage$8,3132%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oyster Point Pharma, Inc. | 79 | $420,756 |
| Bausch & Lomb Americas Inc. | 30 | $21,790 |
| Sun Pharmaceutical Industries Inc. | 36 | $18,694 |
| Kala Pharmaceuticals, Inc. | 24 | $14,909 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $14,335 |
| Alcon Research LLC | 1 | $9,102 |
| Shire North American Group Inc | 7 | $7,023 |
| GSK | 1 | $5,850 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $4,352 |
| Genentech USA, Inc. | 4 | $3,554 |
| Dompe US, Inc. | 5 | $3,188 |
| Bausch Health US, LLC | 1 | $2,762 |
| Novartis | 4 | $2,525 |
| Tearlab Corp | 4 | $2,175 |
| Apellis Pharmaceuticals, Inc. | 1 | $2,033 |
| Alcon | 22 | $797 |
| Thea Pharma Inc. | 4 | $391 |
| AbbVie(2 entities) | 14 | $263 |
| Carl Zeiss Meditec, Inc. | 3 | $236 |
| Harrow Eye, LLC | 2 | $174 |
| Biotissue Holdings Inc. | 5 | $131 |
| Glaukos Corporation | 3 | $105 |
| Rxsight Inc | 3 | $79 |
| Tarsus Pharmaceuticals, Inc. | 1 | $56 |
| Sight Sciences, Inc. | 2 | $51 |
| Rayner Intraocular Lenses Limited | 2 | $32 |
| Optos, Inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $16 |
| Lensar, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ryzumvi$419,144
- CEQUA$15,046
- Tecnis IOL$9,502
- ENVISTA$8,952
- SHINGRIX$5,850
- LOTEMAX SM$4,767
- INVELTYS$4,293
- Tecnis Simplicity$4,050
- Lucentis$3,554
- Oxervate$3,129
- BROMSITE$3,125
- XIIDRA$2,956
- MIEBO$2,206
- TearLab Osmolarity System$2,124
- Syfovre$2,033
- STELLARIS$600
- IYUZEH$309
- enVista MX60 IOL$237
- VisuMax$123
- ARTEVO 800$123
How this compares
$535,427 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 44 | $654 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Chesterfield
- Nancy HolekampChesterfield$2.7M
- Mujtaba QaziChesterfield$334K
- Paul TesserChesterfield$29K
- Ibrahim Sayed-AhmedChesterfield$9K
- Steven SilversteinKansas City$1.6M
- Joseph TauberKansas City$1.3M
- Steven CouchSaint Louis$1.2M
- Andrew MoyesKansas City$1.1M
- Ranjan MalhotraSaint Louis$964K
- Navin TekwaniSaint Louis$957K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.